Liposomes conjugated with anti-AOC3 antibodies have been used as targeted drug delivery systems in colorectal cancer to enhance the specificity and efficiency of treatment. Studies indicate that this conjugation helps concentrate drugs at the tumor site, reducing damage to normal cells. This approach has demonstrated stronger anti-tumor effects and significantly reduced side effects. Such liposomes provide new prospects for targeted therapy in colorectal cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-261 | Anti-Human AOC3 Recombinant Antibody (Vapaliximab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG2 |
There are currently no Customer reviews or questions for VS-1024-FY142. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.